Information Provided By: 
Fly News Breaks for January 4, 2018
INSM
Jan 4, 2018 | 07:57 EDT
Baird analyst Brian Skorney raised his price target on Insmed to $42 from $32 following the release of positive additional data on its INS-312 drug candidate. The analyst expects an NDA to be filed by the end of Q1 versus prior guidance of by the end of the first half of the year. Skorney reiterated his Outperform rating on Insmed shares.
News For INSM From the Last 2 Days
There are no results for your query INSM
